Journal Article DZNE-2025-00437

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Perivascular space and white matter hyperintensities in Alzheimer's disease: associations with disease progression and cognitive function.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2025
BioMed Central London

Alzheimer's research & therapy 17(1), 62 () [10.1186/s13195-025-01707-9]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: Alzheimer's disease (AD) is the leading cause of dementia, characterized by the accumulation of amyloid-beta (Aβ) and neurofibrillary tangles. Recent studies emphasize the role of vascular factors, including the glymphatic system, in AD pathogenesis, particularly in Aβ clearance. The diffusion tensor image analysis along the perivascular space (DTI-ALPS; ALPS-Index) has emerged as a novel, non-invasive method to evaluate the glymphatic system in vivo, showing glymphatic insufficiency in AD. This study aimed to investigate alterations in the function of the glymphatic system in individuals with AD versus healthy controls (HC), and to explore its association with Aβ, cerebrovascular disease (CVD), white matter hyperintensities (WMH), and cognitive function.DTI MRI data from three independent study cohorts (ActiGliA: AD n = 16, Controls n = 18; DELCODE: AD n = 54, Controls n = 67; ADNI: AD n = 43, Controls n = 49) were used to evaluate the perivascular space (PVS) integrity; a potential biomarker for glymphatic activity. The DTI-Along the Perivascular Space technique was used to measure water diffusion along PVS providing an index to assess the efficiency of the glymphatic system's waste clearance function. WMH load was quantified in FLAIR MRI using the lesion segmentation tool. We quantified WMHs volume within our defined region of interest (ROI) and excluded participants with any WMHs to avoid confounding the ALPS-Index. Associations with cerebrospinal fluid (CSF) AD hallmark biomarkers, cognitive performance (MMSE) and clinical severity (CDR) were assessed.AD patients had a significantly lower ALPS-Index vs. healthy controls (ActiGliA: AD: mean = 1.22, SD = 0.12; Controls: mean = 1.36, SD = 0.14, p = 0.004; DELCODE: AD: mean = 1.26, SD = 0.18; Controls: mean = 1.34, SD = 0.2, p = 0.035; ADNI: AD: mean = 1.08, SD = 0.24; Controls: mean = 1.19, SD = 0.13, p = 0.008). The ALPS-Index was associated with CSF Aβ concentration, WMH number and MMSE and CDR. WMH, found in the ROIs correlated negatively with the ALPS-Index.This study highlights the potential of the DTI-ALPS-Index as a biomarker for glymphatic dysfunction in AD. It underscores the importance of considering vascular factors and the glymphatic system in the pathogenesis and diagnosis of AD as WMHs in the ROI could cause disturbances and inaccurate indices.

Keyword(s): Humans (MeSH) ; Alzheimer Disease: diagnostic imaging (MeSH) ; Alzheimer Disease: pathology (MeSH) ; Female (MeSH) ; Male (MeSH) ; White Matter: diagnostic imaging (MeSH) ; White Matter: pathology (MeSH) ; Aged (MeSH) ; Disease Progression (MeSH) ; Glymphatic System: diagnostic imaging (MeSH) ; Glymphatic System: pathology (MeSH) ; Diffusion Tensor Imaging: methods (MeSH) ; Cognition: physiology (MeSH) ; Aged, 80 and over (MeSH) ; Amyloid beta-Peptides: cerebrospinal fluid (MeSH) ; Amyloid beta-Peptides: metabolism (MeSH) ; Magnetic Resonance Imaging: methods (MeSH) ; Brain: diagnostic imaging (MeSH) ; Brain: pathology (MeSH) ; Alzheimer's disease ; Amyloid-beta ; Cognitive decline ; Dementia ; Diffusion tensor imaging ; Perivascular space ; Amyloid beta-Peptides

Classification:

Contributing Institute(s):
  1. Molecular Neurobiology (AG Simons)
  2. Vascular Cognitive Impairment & Post-Stroke Dementia (AG Dichgans)
  3. Clinical Research (Munich) (Clinical Research (Munich))
  4. Vascular Pathology (AG Dirnagl)
  5. Interdisciplinary Dementia Research (AG Endres)
  6. Translational Neuropsychiatry (AG Priller)
  7. Translational Dementia Research (Bonn) (AG Schneider)
  8. Clinical Alzheimer’s Disease Research (AG Jessen)
  9. Patient Studies (Bonn) (Patient Studies (Bonn))
  10. Clinical Neurophysiology and Memory (AG Düzel)
  11. Clinical Dementia Research (Rostock /Greifswald) (AG Teipel)
  12. Parkinson Genetics (AG Gasser)
  13. Core ICRU (ICRU)
Research Program(s):
  1. 351 - Brain Function (POF4-351) (POF4-351)
  2. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)
  3. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2025
Database coverage:
Medline ; Creative Commons Attribution CC BY 4.0 ; DOAJ ; OpenAccess ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Institute Collections > M DZNE > M DZNE-Clinical Research (Munich)
Institute Collections > BN DZNE > BN DZNE-Patient Studies (Bonn)
Document types > Articles > Journal Article
Institute Collections > BN DZNE > BN DZNE-AG Schneider
Institute Collections > ROS DZNE > ROS DZNE-AG Teipel
Institute Collections > TÜ DZNE > TÜ DZNE-AG Gasser
Institute Collections > BN DZNE > BN DZNE-AG Jessen
Institute Collections > MD DZNE > MD DZNE-AG Düzel
Institute Collections > M DZNE > M DZNE-AG Dichgans
Institute Collections > B DZNE > B DZNE-AG Priller
Institute Collections > B DZNE > B DZNE-AG Dirnagl
Institute Collections > M DZNE > M DZNE-AG Simons
Institute Collections > B DZNE > B DZNE-AG Endres
Institute Collections > TÜ DZNE > TÜ DZNE-ICRU
Full Text Collection
Public records
Publications Database

 Record created 2025-03-19, last modified 2025-03-23